Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2019 within the United States, there will be approximately 228,150 new cases of lung cancer and about 142,670 deaths from this disease. More than half of patients die within 1 year of diagnosis, and 5-year survival is around 17.8%. Utilization of recently approved immune-checkpoint inhibitors in treatment regimens for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival.
Within this educational activity, clinical experts will discuss checkpoint inhibitors in NSCLC with an emphasis on therapy timing, sequencing, and combining of treatments. Discussion will also include utilization of these agents in SCLC, detailing the clinical implications of the latest study results.